Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
Rosenthal
Rachel
R
Department of Surgery, Kantonspital Olten, Switzerland.
Viehl
Carsten T
CT
Guller
Ulrich
U
Weber
Walter P
WP
Adamina
Michel
M
Spagnoli
Giulio C
GC
Heberer
Michael
M
Zuber
Markus
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D003606:Dacarbazine / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology; D000939:Epitopes / Q000276:immunology; D005732:Gangliosides / Q000276:immunology; D016233:Immunotherapy, Active / Q000379:methods*; D007372:Interferons / Q000627:therapeutic use; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D014616:Vaccinia virus / Q000276:immunology
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D019496:Cancer Vaccines; D000939:Epitopes; D005732:Gangliosides; D003606:Dacarbazine; D007372:Interferons